180 related articles for article (PubMed ID: 24520075)
1. Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids.
Perrino E; Steiner M; Krall N; Bernardes GJ; Pretto F; Casi G; Neri D
Cancer Res; 2014 May; 74(9):2569-78. PubMed ID: 24520075
[TBL] [Abstract][Full Text] [Related]
2. Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates.
Gébleux R; Wulhfard S; Casi G; Neri D
Mol Cancer Ther; 2015 Nov; 14(11):2606-12. PubMed ID: 26294742
[TBL] [Abstract][Full Text] [Related]
3. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
[TBL] [Abstract][Full Text] [Related]
4. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
[TBL] [Abstract][Full Text] [Related]
5. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM
Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201
[TBL] [Abstract][Full Text] [Related]
6. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
Hess C; Neri D
Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
[TBL] [Abstract][Full Text] [Related]
7. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.
Pasche N; Wulhfard S; Pretto F; Carugati E; Neri D
Clin Cancer Res; 2012 Aug; 18(15):4092-103. PubMed ID: 22693354
[TBL] [Abstract][Full Text] [Related]
8. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
9. Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids.
Nittoli T; Kelly MP; Delfino F; Rudge J; Kunz A; Markotan T; Spink J; Chen Z; Shan J; Navarro E; Tait M; Provoncha K; Giurleo J; Zhao F; Jiang X; Hylton D; Makonnen S; Hickey C; Kirshner JR; Thurston G; Papadopoulos N
Bioorg Med Chem; 2018 May; 26(9):2271-2279. PubMed ID: 29605304
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of
Hartimath SV; Alizadeh E; Solomon VR; Chekol R; Bernhard W; Hill W; Parada AC; Barreto K; Geyer CR; Fonge H
J Nucl Med; 2019 Aug; 60(8):1103-1110. PubMed ID: 30655327
[TBL] [Abstract][Full Text] [Related]
11. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.
Haddish-Berhane N; Shah DK; Ma D; Leal M; Gerber HP; Sapra P; Barton HA; Betts AM
J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):557-71. PubMed ID: 23933716
[TBL] [Abstract][Full Text] [Related]
12. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.
Villa A; Trachsel E; Kaspar M; Schliemann C; Sommavilla R; Rybak JN; Rösli C; Borsi L; Neri D
Int J Cancer; 2008 Jun; 122(11):2405-13. PubMed ID: 18271006
[TBL] [Abstract][Full Text] [Related]
13. Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability.
Poon KA; Flagella K; Beyer J; Tibbitts J; Kaur S; Saad O; Yi JH; Girish S; Dybdal N; Reynolds T
Toxicol Appl Pharmacol; 2013 Dec; 273(2):298-313. PubMed ID: 24035823
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma.
Nguyen M; Miyakawa S; Kato J; Mori T; Arai T; Armanini M; Gelmon K; Yerushalmi R; Leung S; Gao D; Landes G; Haak-Frendscho M; Elias K; Simmons AD
Clin Cancer Res; 2015 Dec; 21(24):5552-62. PubMed ID: 26240273
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates.
Wada R; Erickson HK; Lewis Phillips GD; Provenzano CA; Leipold DD; Mai E; Johnson H; Tibbitts J
Cancer Chemother Pharmacol; 2014 Nov; 74(5):969-80. PubMed ID: 25186956
[TBL] [Abstract][Full Text] [Related]
16. Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix.
Gébleux R; Stringhini M; Casanova R; Soltermann A; Neri D
Int J Cancer; 2017 Apr; 140(7):1670-1679. PubMed ID: 27943268
[TBL] [Abstract][Full Text] [Related]
17. Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.
Sapra P; Betts A; Boni J
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):541-55. PubMed ID: 23978126
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
Tassone P; Gozzini A; Goldmacher V; Shammas MA; Whiteman KR; Carrasco DR; Li C; Allam CK; Venuta S; Anderson KC; Munshi NC
Cancer Res; 2004 Jul; 64(13):4629-36. PubMed ID: 15231675
[TBL] [Abstract][Full Text] [Related]
19. Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.
Kellogg BA; Garrett L; Kovtun Y; Lai KC; Leece B; Miller M; Payne G; Steeves R; Whiteman KR; Widdison W; Xie H; Singh R; Chari RV; Lambert JM; Lutz RJ
Bioconjug Chem; 2011 Apr; 22(4):717-27. PubMed ID: 21425776
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
